Ariad, Otsuka Pharmaceutical deal

Otsuka received exclusive rights to commercialize and co-develop Iclusig ponatinib from Ariad in 10 Asian territories to treat resistant and intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The territories are Japan, China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam. Ariad will receive $77.5 million up front. The company is eligible for a milestone payment for Japanese approval to treat resistant and intolerant Ph+ leukemias and additional milestone payments upon approval in different indications, plus royalties. ...